Dihexa vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in April 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- NNZ-2591 has stronger research evidence (Human Trials) compared to Dihexa (Animal Studies).
Detailed Comparison
| Attribute | Dihexa | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 5-20 mg daily Once daily | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Oral, sublingual, or intranasal | Oral liquid |
| Typical Duration | Cycles of 2-4 weeks | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Morning | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats (J Pharmacol Exp Ther, 2013; this paper carries a 2021 expression of concern but is not retracted). A 2014 JPET study tied the procognitive and synaptogenic effects to the HGF/c-Met system, but that paper was retracted in April 2025, together with the 2012 paper that first proposed dihexa as an HGF/Met modifier, after the journal had flagged them with expressions of concern in 2021. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. The often repeated 'millions of times more potent than BDNF' line comes from a single cell assay and should not be read as a clinical fact. Treat dihexa as a research molecule with interesting but shaken animal data, not as a proven cognitive enhancer. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: Dihexa vs NNZ-2591
What is the difference between Dihexa and NNZ-2591?
Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in april 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.